Quality of life after several treatments for osteoarthritis of the hip

Kawasaki, Masashi; Hasegawa, Yukiharu; Sakano, Shinji; Torii, Yukio; Warashina, Hideki

doi:10.1007/s007760300005

Cited by 21 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, although in the first year THR was better than non-surgical treatment, by 5 years this benefit was reversed. 98 Because the study had a very small sample size (62 v 45) and no adjustment for confounders, the results are subject to bias. Two other cohort studies have been undertaken, one comparing WOMAC and SF-36 scores 99 and the other comparing survival rates 100 between patients with THR and the source populations.…”

Section: Joint Replacement Has To Be Considered In Patients With Radimentioning

confidence: 99%

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Zhang

2005

Annals of the Rheumatic Diseases

767

503

View full text Add to dashboard Cite

Objective: To develop evidence based recommendations for the management of hip osteoarthritis (OA). Methods: The multidisciplinary guideline development group comprised 18 rheumatologists, 4 orthopaedic surgeons, and 1 epidemiologist, representing 14 European countries. Each participant contributed up to 10 propositions describing key clinical aspects of hip OA management. Ten final recommendations were agreed using a Delphi consensus approach. Medline, Embase, CINAHL, Cochrane Library, and HTA reports were searched systematically to obtain research evidence for each proposition. Where possible, outcome data for efficacy, adverse effects, and cost effectiveness were abstracted. Effect size, rate ratio, number needed to treat, and incremental cost effectiveness ratio were calculated. The quality of evidence was categorised according to the evidence hierarchy. The strength of recommendation was assessed using the traditional A-D grading scale and a visual analogue scale. Results: Ten key treatment propositions were generated through three Delphi rounds. They included 21 interventions, such as paracetamol, NSAIDs, symptomatic slow acting disease modifying drugs, opioids, intra-articular steroids, non-pharmacological treatment, total hip replacement, osteotomy, and two general propositions. 461 studies were identified from the literature search for the proposed interventions of efficacy, side effects, and cost effectiveness. Research evidence supported 15 interventions in the treatment of hip OA. Evidence specific for the hip was strikingly lacking. Strength of recommendation varied according to category of research evidence and expert opinion. Conclusion: Ten key recommendations for the treatment of hip OA were developed based on research evidence and expert consensus. The effectiveness and cost effectiveness of these recommendations were evaluated and the strength of recommendation was scored.

show abstract

Section: Joint Replacement Has To Be Considered In Patients With Radimentioning

confidence: 99%

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Zhang

2005

Annals of the Rheumatic Diseases

767

503

View full text Add to dashboard Cite

show abstract

“…Although most patients with hip OA undergo conservative treatment, the studies of hip OA have so far been focused on before and after surgery (Kawasaki et al, 2003;Yanagimoto et al, 2005;Toyama et al, 2000;Fortin et al, 1999;Kiebzak et al, 2002;Fitzgerald et al, 2004). In addition, many of the studies specialize in range of motion or symptoms determined by the evaluation chart of hip joint functioning developed by the Japanese Orthopaedic Association referred to as the JOA Score (Tanaka et al, 1997) and few of them are focused on the patients' daily life or mentality.…”

Section: Introductionmentioning

confidence: 99%

A study of the reality of daily life among patients with osteoarthritis of the hip undergoing conservative treatment

Koyama

Irie

Takatori

et al. 2007

Journal of Orthopaedic Nursing

View full text Add to dashboard Cite

“…Although some patients should be managed conservatively with medical treatment, many will face considerable disability from progressive loss of hip or knee function. For these individuals, elective arthroplasties of the hips and knees improve quality of life [7,12]. Some authors argue replacement should be considered with ''radiographic evidence of joint damage and moderate to severe persistent pain or disability, or both'' [9].…”

Section: Introductionmentioning

confidence: 99%

Utilization of Elective Hip and Knee Arthroplasty by Age and Payer

Matlock

Earnest

Epstein³

2008

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Elective joint arthroplasty improves the quality of life for patients with severe arthritis. In the United States, utilization of services varies with insurance status. We asked the following questions: (1) Is there an increase in the utilization of elective hip and knee arthroplasty after age 65? (2) Does the difference in utilization between the insured and general populations decrease at age 65 (the age at which Medicare provides near universal coverage)? (3) Does Medicare become the primary payer of elective hip and knee arthroplasty after the age of 65? We used the National Inpatient Sample to identify patients and payers of elective hip and knee arthroplasties by age. We analyzed these data using regression models. At age 65, there was an upward shift in the incidence of arthroplasties in the general and the insured populations and the difference between these two populations decreased. Medicare was the primary payer for the majority of arthroplasties after age 65. We conclude at age 65 the following occurs: (1) utilization of elective joint arthroplasty increases; (2) the difference between the insured population and the general population decreases; and (3) Medicare becomes the primary payer of arthroplasties.

show abstract

Quality of life after several treatments for osteoarthritis of the hip

Cited by 21 publications

References 17 publications

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

A study of the reality of daily life among patients with osteoarthritis of the hip undergoing conservative treatment

Utilization of Elective Hip and Knee Arthroplasty by Age and Payer

Contact Info

Product

Resources

About